AstraZeneca Sells Revenue Stream From Humira To Royalty Pharma For $700 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca says it will use proceeds from the deal to reinvest in biologics.
You may also be interested in...
AstraZeneca Halts NXY-059 Development Following SAINT II Stroke Results
Firm returns the neuroprotectant to partner Renovis after pivotal trial in acute ischemic stroke fails to show statistical significance.
AstraZeneca Halts NXY-059 Development Following SAINT II Stroke Results
Firm returns the neuroprotectant to partner Renovis after pivotal trial in acute ischemic stroke fails to show statistical significance.
Crohn’s Competition Coming
Humira filing will challenge J&J’s Remicade as Crohn’s disease treatment.